We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

AutoLogous Human CArdiac-Derived Stem Cell to Treat Ischemic cArdiomyopathy (ALCADIA) (ALCADIA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00981006
Recruitment Status : Completed
First Posted : September 21, 2009
Last Update Posted : April 1, 2015
Information provided by (Responsible Party):

Study Description
Brief Summary:
The aim of this study is to evaluate the safety and efficacy on the transplantation of autologous human cardiac-derived stem cells (hCSCs) with the controlled release of basic fibroblast growth factor (bFGF) to severe refractory heart failure patients with chronic ischemic cardiomyopathy concordance with reduced left ventricular dysfunction (15%≦LVEF≦35%).

Condition or disease Intervention/treatment Phase
Congestive Heart Failure Ischemic Cardiomyopathy Ventricular Dysfunction Procedure: human cardiac stem cells Phase 1

Detailed Description:
Autologous human stem or progenitor cells of different lineage have been subjected to clinical trials in the past to treat patients with ischemic cardiomyopathy. Although human stem or progenitor cells transplantation had functional benefits in the recovery in experimental myocardial infarction, the major barrier limiting its clinical application is the death of the most of the transplanted cells and poor cardiac differentiation in the host environment. Using the identical technique as clonally cell isolation from experimental animals, we generated human cardiac-derived stem cell (hCSC) enriched Es-marker genes with mesenchymal features. hCSCs included in cell populations accelerating proliferation in the presence of basic fibroblast growth factor (bFGF) on plastic plates are generated from human heart tissues through endomyocardial biopsy. Giving a patient their own hCSCs is an investigational procedure that has been approved by the committee of the Ministry of Health, Labour, and Welfare of Japan for this study. hCSCs have excellent potential to proliferate and regenerate to cardiomyocyte compared with other cells, e.g. myoblasts, bone marrow mononuclear cells and bone marrow stem cells, already evaluated in preliminary experiments on the repair of injured heart muscle. bFGF possesses properties to promote stem cell proliferation, and formation of sufficient microvascular network created by bFGF is critical for long-term survival of transplanted donor cells. This will be the first trial on the use of autologous hCSCs for the treatment of refractory heart failure with chronic ischemic cardiomyopathy. This trial is translational pilot study for looking into the safety and efficacy on the use of autologous hCSCs with the controlled release of bFGF using a gelatin hydrogel sheet.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Hybrid Biotherapy Involving Autologous Human Cardiac Stem Cell Transplantation Combined With the Controlled Release of bFGF Using a Gelatin Hydrogel Sheet to Treat Severe Refractory Heart Failure With Chronic Ischemic Cardiomyopathy
Study Start Date : April 2010
Primary Completion Date : March 2013
Study Completion Date : March 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: human cardiac stem cell therapy
single administration of 0.5 million cells/kg(patient body weight) of human cardiac stem cells and 200 microgram of bFGF at coronary artery bypass grafting (CABG)
Procedure: human cardiac stem cells
Single intramyocardial Injection of autologous hCSCs : 20 cites of infarcted myocardium Implantation of gelatin hydrogel sheet incorporating bFGF: 200 microgram. CABG surgery.
Other Names:
  • human cardiac stem cell (hCSC)
  • human recombinant basic fibroblast growth factor (bFGF)
  • coronary artery bypass grafting (CABG)

Outcome Measures

Primary Outcome Measures :
  1. The primary objective is to evaluate the safety of autologous cardiac-derived stem cells administered by intra-myocardial injection with the controlled release of bFGF in severe refractory heart failure patients with chronic ischemic cardiomyopathy. [ Time Frame: 12 month ]

Secondary Outcome Measures :
  1. The secondary objective is to demonstrate the safety of autologous cardiac-derived stem cells administered by intra-myocardial injection with the controlled release of bFGF in severe refractory heart failure patients with chronic ischemic cardiomyopathy. [ Time Frame: 12month ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Clinical diagnosis of ischemic cardiomyopathy

    • Ischemic cardiomyopathy with old myocardial infarction due to coronary artery atherosclerotic disease.
  2. Age: 20 to 80 years old
  3. left ventricle (LV) dysfunction : An ejection fraction (EF)≧15%, and ≦35% assessed by echocardiography
  4. Refractory heart failure: American Heart Association (AHA)/American College of Cardiology (ACC)heart failure Stage D
  5. Heart failure symptom: New York Heart Association (NYHA) Class III or IV
  6. An indication for CABG:A myocardial ischemia according to major coronary artery stenosis (>75%)
  7. Viability in the infarct area as measured by cardiac delayed hyperenhancement magnetic resonance imaging (MRI)

    • Infarct area affecting >2 contiguous LV segments in a 18-segment model
    • The number of segments which transmural extent of hyperenhancement more than 51% is less than one.

      • Ex1. infarct area with or without bypass graft.
      • Ex2. no correlation with graft number.
      • Ex3. in case of multiple myocardial infarction, an indication for larger in infarct volume.
  8. written informed consent

Exclusion Criteria:

  1. New onset of myocardial infarction or unstable angina within 28 days prior to study entry
  2. Indication for surgical ventricular reconstruction or mitral valve repair *1
  3. Contraindication for endomyocardial biopsy *2
  4. Evidence for malignant disease within 3 years prior to study entry
  5. Chronic hemodialysis
  6. Liver Cirrhosis (ICGR 15 >30%)
  7. Uncontrollable diabetes mellitus (HbA1c>8.0)
  8. Maximum diameter of Aortic aneurysm more than 5.5 cm.(including dissecting aneurysm)
  9. Cardiogenic shock
  10. Active infection (including cytomegalovirus infection)
  11. Drug or alcoholic dependency
  12. Positive for HIV antigen
  13. Active bleeding state (gastric ulcer, cerebral bleeding, etc.)
  14. Gelatin allergy *3
  15. Chromosomal abnormality

    • 1 an indication for LV aneurysmectomy; patients with over 2 segments of dyskinesis area
    • 2 contra-indication for endomyocardial biopsy

      • cardiogenic shock
      • end-stage or uncontrollable congestive heart failure without continues infusion of catecholamine
      • complete or mobitz type atria-ventricular block
    • 3 The screening of gelatin allergy is necessary for all patients by gelatin patch test and gelatin-immunoglobulin E.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00981006

Kyoto Prefectural University School of Medicine
Kyoto, Kajii-cho 465, hirokoji-agaru, kawaramachi-dori,kamikyoku, Japan, 602-8566
National Cardiovascular Center
Osaka, Japan
Sponsors and Collaborators
Naofumi Takehara
National Cerebral and Cardiovascular Center
Translational Research Informatics Center, Kobe, Hyogo, Japan
Asahikawa Medical College
Principal Investigator: Hiroaki Matsubara, MD,PhD Kyoto Prefectural University School of Medicine
More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Naofumi Takehara, Assistant Professor, Kyoto Prefectural University of Medicine
ClinicalTrials.gov Identifier: NCT00981006     History of Changes
Obsolete Identifiers: NCT01697033
Other Study ID Numbers: TRICAD0910
TRICAD0806 ( Registry Identifier: TRI )
First Posted: September 21, 2009    Key Record Dates
Last Update Posted: April 1, 2015
Last Verified: March 2015

Keywords provided by Naofumi Takehara, Kyoto Prefectural University of Medicine:
ischemic cardiomyopathy (ICM)

Additional relevant MeSH terms:
Heart Failure
Ventricular Dysfunction
Heart Diseases
Cardiovascular Diseases
Pathologic Processes